Results 241 to 250 of about 28,689 (318)

JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases. [PDF]

Dermatol Res Pract
Bahramian S, Fazeli P, Rafati A, Demokri S, Memari H, Soheili A, Esmaeili F, Pourmehdi Ardebili M, Erfani H, Vahabi SM.   +9 more
europepmc   +1 more source

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis [PDF]

, 2017
Cerchione, Claudio, Martinelli, Vincenzo, Nappi, Davide, Pane, Fabrizio, Pareto, Anna Emanuele, Peluso, Ilaria, Picardi, Marco   +6 more
core   +1 more source

Faculty Opinions recommendation of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

, 2017
John R. Wingard, Maxim Norkin
openalex   +2 more sources

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies [PDF]

, 2014
DiPersio, John F, et al,
core   +1 more source

Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure

, 2018
Yangyang Ding, Julie W. Stern, Tracey Jubelirer, Gerald Wertheim, Fumin Lin, Fengqi Chang, Zhaohui Gu, Charles G. Mullighan, Yong Li, Richard C. Harvey, I‐Ming Chen, Cheryl L. Willman, Stephen P. Hunger, Marilyn M. Li, Sarah K. Tasian   +14 more
openalex   +2 more sources

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. [PDF]

Nat Commun
Maslah N, Kaci N, Roux B, Alexe G, Marie R, Pasquer H, Verger E, De Oliveira RD, Culeux C, Mlayah B, Gauthier N, Gonzales F, Zhao LP, Ganesan S, Gou P, Ling F, Soret-Dulphy J, Parquet N, Vainchenker W, Raffoux E, Padua RA, Giraudier S, Marty C, Plo I, Lobry C, Stegmaier K, Puissant A, Kiladjian JJ, Cassinat B, Benajiba L.   +29 more
europepmc   +1 more source

Which myelofibrosis patients benefit from treatment with ruxolitinib? A single-center experience. [PDF]

Arch Med Sci
Belohlavkova P, Zak P, Radocha J.
europepmc   +1 more source

Granulocyte colony-stimulating factor potentiates all- retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A [PDF]

core   +1 more source

Efficacy of emapalumab in treating 3 pediatric patients with epstein-barr virus-associated hemophagocytic lymphohistiocytosis complicated by multiple organ dysfunction. [PDF]

Ann Med
Liu G, Qian S, Liu J, Ma H, Wang Q.
europepmc   +1 more source

Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model

, 2018
Sanghoon Lee, Tishi Shah, Changhong Yin, Jessica Hochberg, Janet Ayello, Erin Morris, Carmella van de Ven, Mitchell S. Cairo   +7 more
openalex   +2 more sources